SPOTLIGHT -
Dr. Allaf on Evaluating the PROSPER-RCC Trial Results in RCC
Mohamad Ezzeddine Allaf, MD, discusses several key considerations when interpreting and extrapolating initial results from the phase 3 PROSPER-RCC trial in renal cell carcinoma.
Read More
Dr Allaf on Perioperative Nivolumab Vs Observation Following Nephrectomy in RCC
Mohamad Ezzeddine Allaf, MD, discusses the results of perioperative nivolumab vs observation in patients with renal cell carcinoma who undergo nephrectomy.
Dr Berkenstock on ADC-Related Ocular Toxicities in Cervical and Ovarian Cancers
Dr Matalonis on the Management of Mirvetuximab Soravtansine-Related Toxicities in FRα+ Ovarian Cancer
Updated EMPOWER-Lung 3 Data Support Frontline Cemiplimab Plus Chemo in Advanced NSCLC
Neoadjuvant Nivolumab Plus Chemotherapy Retains EFS Advantage in Resectable NSCLC
